Status:
UNKNOWN
Aprepitant to Mitigate Opioids' Cognitive Side Effects
Lead Sponsor:
University of Arizona
Conditions:
Cognitive Dysfunction
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Morphine and similar substances (called opioids) are often prescribed for moderate to severe pain, such as after a surgery, thus allowing for minimal pain and a better recovery. Unfortunately various,...
Detailed Description
In this proposed study the investigators want to examine if the drug aprepitant can decrease the so called "cognitive impairments" opioids may cause, such as drowsiness, loopiness and feeling "high". ...
Eligibility Criteria
Inclusion
- healthy English speaking, opioid-naive consenting adults
Exclusion
- current or very recent (\< 3 months) opioid therapy
- morbid obesity
- liver disease
- therapy with pimozide, terfenadine, astemizole, cisapride, vitamin K antagonists (warfarin), hormonal contraceptives
- acute or chronic infections
- immunocompromised status
- hemodynamically unstable, hemorrhage (bleeding)
- recent surgery
- pregnancy, nursing
- younger than 18 years old
- not proficient of the English language
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02226601
Start Date
October 1 2014
Last Update
June 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona Medical Center
Tucson, Arizona, United States, 85724